Drug maker Formycon announced today that it has begun a phase 1 clinical trial of its proposed ustekinumab biosimilar, FYB202, referencing Stelara. Ustekinumab is the first available therapy to target the interleukin-12 and -23 pathway.
Drug maker Formycon announced today that it has begun a phase 1 clinical trial of its proposed ustekinumab biosimilar, FYB202, referencing Stelara. Ustekinumab is the first available therapy to target the interleukin-12 and -23 pathway.
The reference drug is FDA-approved to treat inflammatory conditions including Crohn disease, psoriatic arthritis, and plaque psoriasis. Stelara’s sponsor, Janssen, announced last week that the FDA has also approved the product for the treatment of ulcerative colitis.
Formycon’s phase 1 trial, which began dosing participants last week, is sponsored by Bioeq GmbH, which conducted the trial design and is handling clinical operation. Formycon is developing the biosimilar in partnership with Aristo Pharma GmbH.
If the phase 1 trial and a subsequent phase 3 confirmatory trial prove to be successful and lead to regulatory approval, Formycon indicated in a statement, the biosimilar could launch after Stelara’s patent exclusivity ends in September 2023 in the United States and in July 2024 in the European Union.
In addition to its proposed ustekinumab product, Formycon is also developing proposed biosimilars of ranibizumab, referencing Lucentis; aflibercept, referencing Eylea; and an undisclosed biologic product.
Formycon is the second biosimilar developer to announce a clinical trial of a ustekinumab biosimilar in recent weeks; earlier this month, NeuClone indicated that it has also begun dosing participants with its proposed ustekinumab biosimilar in a phase 1 trial. The single-dose, double-blind, randomized, 3-arm, multicenter study is being conducted in Australia in more than 200 healthy volunteers.
According to Formycon, sales of the brand-name Stelara totaled more than $5 billion in 2018 and continue to grow at a rapid rate. Expanding labels for the drug, it adds, offer additional revenue potential in the market.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.